Vaxart Inc Stock Today
| VXRT Stock | USD 0.72 0 0.56% |
Performance0 of 100
| Odds Of DistressOver 82
|
Vaxart is selling for under 0.71600002 as of the 30th of January 2025; that is 0.56 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.71. Vaxart has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 31st of December 2024 and ending today, the 30th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of February 2018 | Category Healthcare | Classification Health Care |
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company is headquartered in South San Francisco, California. Vaxart operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 227.48 M outstanding shares of which 11.62 M shares are at this time shorted by private and institutional investors with about 11.71 trading days to cover. More on Vaxart Inc
Moving together with Vaxart Stock
| 0.68 | PFE | Pfizer Inc Earnings Call This Week | PairCorr |
Moving against Vaxart Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Vaxart Stock Highlights
| CEO President | Steven Lo | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVaxart can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vaxart's financial leverage. It provides some insight into what part of Vaxart's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vaxart Inc (VXRT) is traded on NASDAQ Exchange in USA. It is located in 170 Harbor Way, South San Francisco, CA, United States, 94080 and employs 109 people. Vaxart is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 164.72 M. Vaxart Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 227.48 M outstanding shares of which 11.62 M shares are at this time shorted by private and institutional investors with about 11.71 trading days to cover.
Vaxart Inc currently holds about 129.55 M in cash with (70.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Vaxart Probability Of Bankruptcy
Ownership AllocationVaxart Inc shows a total of 227.48 Million outstanding shares. About 81.33 % of Vaxart outstanding shares are held by general public with 0.87 (%) owned by insiders and only 17.8 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Vaxart Ownership Details
Vaxart Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Jane Street Group Llc | 2024-09-30 | 204.3 K | |
| Raymond James Finl Svs Advisors, Inc. | 2024-09-30 | 188.4 K | |
| Bank Of America Corp | 2024-09-30 | 166.5 K | |
| Monaco Asset Management | 2024-09-30 | 164.3 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 153.5 K | |
| Xtx Topco Ltd | 2024-09-30 | 136.5 K | |
| Goldman Sachs Group Inc | 2024-09-30 | 125.5 K | |
| Two Sigma Investments Llc | 2024-09-30 | 111.1 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 94.7 K | |
| Sio Capital Management, Llc | 2024-09-30 | 13.6 M | |
| Vanguard Group Inc | 2024-09-30 | 10.1 M |
Vaxart Historical Income Statement
Vaxart Stock Against Markets
Vaxart Corporate Management
| Sarah Khan | VP Resources | Profile | |
| Rajesh Kapoor | Senior Quality | Profile | |
| Shaily Garg | Senior Management | Profile | |
| Brant Biehn | Sr Operations | Profile | |
| Cezar MBA | Pres CEO | Profile |
Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.